See more : St. Galler Kantonalbank AG (SGKN.SW) Income Statement Analysis – Financial Results
Complete financial analysis of SELLAS Life Sciences Group, Inc. (SLS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SELLAS Life Sciences Group, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- AVE Science&Technology CO.,LTD (688067.SS) Income Statement Analysis – Financial Results
- Transindia Real Estate Limited (TREL.NS) Income Statement Analysis – Financial Results
- Fortistar Sustainable Solutions Corp. (FSSI) Income Statement Analysis – Financial Results
- Golden Metal Resources PLC (GMET.L) Income Statement Analysis – Financial Results
- Lancor Holdings Limited (LANCORHOL.BO) Income Statement Analysis – Financial Results
SELLAS Life Sciences Group, Inc. (SLS)
About SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 1.00M | 7.60M | 1.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 9.32M | 2.49M | 2.04M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 100.00K | 200.00K | 0.00 | 0.00 | 0.00 | 0.00 | 3.00K | 355.00K | 1.40M | 520.00K | 0.00 | 20.79M | 0.00 | 0.00 | 0.00 | 11.41M | 0.00 |
| Gross Profit | 0.00 | 900.00K | 7.40M | 1.90M | 0.00 | 0.00 | 0.00 | -3.00K | -355.00K | 7.92M | 1.97M | 2.04M | -20.79M | 0.00 | 0.00 | 0.00 | -11.41M | 0.00 |
| Gross Profit Ratio | 0.00% | 90.00% | 97.37% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 84.94% | 79.09% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 24.01M | 30.27M | 21.37M | 9.28M | 7.29M | 18.32M | 6.07M | 19.86M | 23.61M | 28.35M | 21.08M | 14.61M | 11.54M | 7.87M | 8.89M | 7.05M | 6.75M | 1.30M |
| General & Administrative | 13.86M | 12.58M | 11.32M | 9.60M | 9.92M | 12.77M | 15.09M | 12.01M | 10.61M | 31.34M | 14.60M | 6.59M | 6.86M | 8.75M | 8.63M | 4.87M | 3.74M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.39M | 0.00 | 0.00 | 2.63M | 931.00K | 0.00 |
| SG&A | 13.86M | 12.58M | 11.32M | 9.60M | 9.92M | 12.77M | 15.09M | 12.01M | 10.61M | 31.34M | 14.60M | 6.59M | 9.25M | 8.75M | 8.63M | 7.50M | 4.67M | 633.00K |
| Other Expenses | 0.00 | 10.00M | 5.70M | 0.00 | 0.00 | -3.03M | 0.00 | 0.00 | 509.00K | 170.00K | 37.00K | -13.18M | 9.25M | 0.00 | 0.00 | 7.50M | 0.00 | 0.00 |
| Operating Expenses | 37.87M | 42.85M | 32.69M | 18.88M | 17.21M | 31.09M | 21.16M | 31.87M | 34.22M | 60.14M | 35.81M | 21.20M | 20.79M | 16.63M | 17.52M | 14.55M | 11.41M | 2.41M |
| Cost & Expenses | 37.87M | 42.95M | 32.89M | 18.88M | 17.21M | 31.09M | 21.16M | 31.87M | 34.22M | 61.54M | 36.33M | 21.20M | 20.79M | 16.63M | 17.52M | 14.55M | 11.41M | 2.41M |
| Interest Income | 525.00K | 317.00K | 6.00K | 26.00K | 118.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 180.00K | 448.00K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 118.00K | 266.00K | 462.00K | 3.51M | 760.00K | 1.11M | 807.00K | 33.00K | 0.00 | 5.00K | -5.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 37.87M | 457.00K | 1.27M | 377.00K | 17.21M | 22.04M | 3.00K | 3.00K | 355.00K | 440.00K | 452.00K | 49.00K | 163.00K | 172.00K | 162.00K | 131.00K | 36.00K | 0.00 |
| EBITDA | 529.00K | -31.95M | -19.66M | -16.40M | 668.00K | 0.00 | -23.04M | -15.99M | -37.48M | -36.61M | 7.63M | -34.38M | -11.32M | -11.82M | -18.22M | -14.24M | -10.93M | -2.41M |
| EBITDA Ratio | 0.00% | -4,228.20% | -390.08% | -888.53% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -733.32% | 306.71% | -1,040.19% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -37.87M | -41.95M | -25.29M | -16.98M | -20.04M | -31.09M | -23.04M | -31.87M | -34.22M | -52.22M | -33.84M | -21.20M | -20.79M | -16.63M | -17.52M | -14.55M | -11.41M | -2.41M |
| Operating Income Ratio | 0.00% | -4,195.00% | -332.82% | -893.79% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -560.38% | -1,360.68% | -1,040.19% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 529.00K | 649.00K | 4.36M | 208.00K | 668.00K | 2.54M | -7.79M | 5.13M | -4.37M | 13.62M | -41.79M | -13.18M | 9.30M | 4.63M | -867.00K | 180.00K | 448.00K | 0.00 |
| Income Before Tax | -37.34M | -41.30M | -20.94M | -16.77M | -19.37M | -29.05M | -23.50M | -10.86M | -38.59M | -36.61M | -75.63M | -34.38M | -11.49M | -11.99M | -18.39M | -14.37M | -10.97M | -2.41M |
| Income Before Tax Ratio | 0.00% | -4,130.10% | -275.47% | -882.84% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -392.81% | -3,040.85% | -1,686.80% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -649.00K | -237.00K | -17.00K | -81.00K | -1.38M | 253.00K | 243.00K | 365.00K | -15.45M | 1.05M | -1.05M | -9.30M | -4.63M | 867.00K | 0.00 | 25.00K | 0.00 |
| Net Income | -37.34M | -40.65M | -20.70M | -16.76M | -19.29M | -27.67M | -23.75M | -23.55M | -63.90M | -36.61M | -76.68M | -34.97M | -11.49M | -11.99M | -18.39M | -14.37M | -10.99M | -2.41M |
| Net Income Ratio | 0.00% | -4,065.20% | -272.36% | -881.95% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -392.81% | -3,083.15% | -1,715.85% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.34 | -2.10 | -1.34 | -2.10 | -7.54 | -105.80 | -507.49 | -3.55K | -12.35K | -9.20K | -25.51K | -16.80K | -9.48K | -19.60K | -34.05K | -31.38K | -26.04K | -5.73K |
| EPS Diluted | -1.34 | -2.10 | -1.34 | -2.10 | -7.54 | -105.80 | -507.49 | -3.55K | -12.35K | -9.20K | -25.51K | -16.80K | -9.48K | -19.60K | -34.05K | -31.38K | -26.04K | -5.73K |
| Weighted Avg Shares Out | 27.78M | 19.40M | 15.48M | 7.98M | 2.56M | 261.54K | 46.81K | 6.64K | 5.17K | 3.98K | 3.01K | 2.08K | 1.21K | 612.00 | 540.00 | 458.00 | 422.00 | 420.00 |
| Weighted Avg Shares Out (Dil) | 27.78M | 19.40M | 15.48M | 7.98M | 2.56M | 261.54K | 46.81K | 6.64K | 5.18K | 3.98K | 3.01K | 2.08K | 1.21K | 612.00 | 540.00 | 458.00 | 422.00 | 420.00 |
SELLAS Life Sciences Reaches Target Enrollment ex-China in Phase 3 REGAL Trial of Galinpepimut-S in Acute Myeloid Leukemia
NEW YORK, Nov. 29, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced...
SELLAS Life Sciences Receives Favorable FDA Type C Meeting Feedback on Chemistry, Manufacturing, and Controls (CMC) Biologics License Application (BLA) Filing Strategy for Galinpepimut-S (GPS)
– FDA feedback indicates Company's CMC plans are in alignment with FDA's requirements and expectations towards a BLA –
SELLAS Life Sciences Presents Positive Key Immunobiological and Clinical Data from Phase 1/2 Trial of Galinpepimut-S (GPS) in Combination with Keytruda® in WT1+ Platinum-Resistant Advanced Ovarian Cancer at the International Gynecologic Cancer Society 2023 Annual Global Meeting
NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced...
SELLAS Life Sciences Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced...
SELLAS Life Sciences Receives Fast Track Designation from FDA for SLS009 for Treatment of Relapsed/Refractory Peripheral T-cell Lymphomas
- SLS009 Demonstrated Promising Efficacy in Phase 1 Study with 36.4% Clinical Response (ORR) in r/r Peripheral T-cell Lymphomas (PTCL); ORR in r/r PTCL Patients with Standard of Care is 25.8% -
SELLAS Life Sciences to Present Final Data from Phase 1/2 Study of Galinpepimut-S in Combination with Keytruda® (pembrolizumab) in Patients with WT1+ Platinum-Resistant Advanced Ovarian Cancer at the International Gynecologic Cancer Society 2023 Annual Global Meeting
NEW YORK, Oct. 17, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced...
SELLAS Announces Positive Initial Topline Phase 2a Data of SLS009 in Acute Myeloid Leukemia
– SLS009 Is First CDK9 Inhibitor in Combination with AZA/VEN to Achieve Complete Response in AML Patient Resistant to Venetoclax Combination Therapies –
SELLAS Life Sciences Provides Update on Phase 3 REGAL Clinical Trial for Galinpepimut-S in Acute Myeloid Leukemia
- Enrollment ex-China Expected to be Completed in November 2023 – - Enrollment in China Expected to Commence this Quarter - NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”),...
SELLAS Advances Blood Cancer Treatment with “Tremendous Therapeutic Promise”
October 11, 2023 SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) has reported two significant milestones this week as it pursues development of its drug candidate, SLS009 for hematological malignancies. “SLS009 is a novel and highly selective CDK9 inhibitor which, to...
SELLAS Announces First Patient Dosed in Phase Ib/II Trial of SLS009 (GFH009) in Relapsed/Refractory Peripheral T-cell Lymphomas
NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced...
Source: https://incomestatements.info
Category: Stock Reports